2026 Rules Shift Healthcare Private Equity Strategies
2026 regulatory shifts influence private equity's healthcare strategic focus.
Why it matters: Corporate legal teams must adjust compliance and valuations to manage risks and opportunities in a changing landscape.
- California's CPOM laws challenge private equity valuations in healthcare.
- Regulatory shifts influence only 4% of healthcare transactions, downplaying their overall impact.
- ASCs, behavioral health remain key PE targets despite compliance pressures.
- ThinkBRG survey highlights labor costs, operations as primary transaction drivers.
In 2026, private equity (PE) in healthcare is undergoing strategic changes driven by new regulatory landscapes. Compliance with updated laws, particularly those emphasizing diversity, equity, and inclusion, is critical as they affect investment strategies.
Holly Buckley, Chair of Health Care at McGuireWoods, emphasizes that PE firms now focus on building compliance infrastructure, aligning with physicians, and leveraging technology. This represents a shift toward strategic integration over aggressive acquisitions.
Specific regulatory challenges include California's corporate practice of medicine (CPOM) laws, which require a clear separation between medical practices and investor influence. These laws are significant in deal valuations and structures, impacting PE firms' operational strategies.
Despite the regulatory environment, ThinkBRG survey data reveals that regulatory shifts are the primary driver in only 4% of healthcare transactions. Other factors, especially labor costs and operational efficiency, are more influential.
Subsectors like ambulatory surgery centers (ASCs) and behavioral health remain attractive due to favorable reimbursement models and increasing demand. PE firms invest significantly here, navigating compliance regulations to capture growth opportunities.
For corporate legal teams, understanding and adapting to these regulatory changes is essential. Developing agile compliance strategies and reassessing investment valuations will be crucial for managing risks and optimizing outcomes in this evolving environment.
By the numbers:
- 4% — Healthcare transactions primarily driven by regulatory shifts.
- 96% — Healthcare transactions driven by factors other than regulations.
Yes, but: Compliance will continue to shape deals, though not as the primary driver for most.